» Articles » PMID: 10622313

Selection of Metastatic Tumour Phenotypes by Host Immune Systems

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 2000 Jan 6
PMID 10622313
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Metastasis and the processes underlying this phenomenon make epithelial cancers so malignant. Local control of cancers by surgery is sometimes possible but locoregional and distant recurrence commonly lead to the failure of treatment with ensuing morbidity and mortality. Tumour cells express a range of new antigens during growth and there are opportunities for the host immune system to interact with these antigens. This immune interaction eliminates the tumour or allows selection of phenotypic variants. Cell phenotypes selected by an incomplete immune response resemble the cell type commonly associated with metastases. Thus we propose that the host immune system may be responsible for selection of this phenotype and progression of the disease.

Citing Articles

Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy.

Carretero R, Romero J, Ruiz-Cabello F, Maleno I, Rodriguez F, Camacho F Immunogenetics. 2008; 60(8):439-47.

PMID: 18545995 DOI: 10.1007/s00251-008-0303-5.


Immunoprevention and immunotherapy of cancer in ageing.

Provinciali M, Smorlesi A Cancer Immunol Immunother. 2004; 54(2):93-106.

PMID: 15558281 PMC: 11032815. DOI: 10.1007/s00262-004-0539-3.


Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21.

Maleno I, Cabrera C, Cabrera T, Paco L, Lopez-Nevot M, Collado A Immunogenetics. 2004; 56(4):244-53.

PMID: 15258706 DOI: 10.1007/s00251-004-0692-z.


Evolving immunotherapeutic strategies in bladder and renal cancer.

Griffiths T, Mellon J Postgrad Med J. 2004; 80(944):320-7.

PMID: 15192163 PMC: 1743027. DOI: 10.1136/pgmj.2003.013508.


T cell adhesion and cytolysis of pancreatic cancer cells: a role for E-cadherin in immunotherapy?.

French J, Cresswell J, Wong W, Seymour K, Charnley R, Kirby J Br J Cancer. 2002; 87(9):1034-41.

PMID: 12434297 PMC: 2364324. DOI: 10.1038/sj.bjc.6600597.